BACKGROUND: The role of day 14 (D14) bone marrow (BM) assessment in detecting increased blasts in patients undergoing induction for acute lymphoblastic leukemia (ALL) is not well defined. METHODS: This study evaluated 389 adolescent and adult patients with previously untreated Philadelphia chromosome-negative ALL who received frontline induction chemotherapy and for whom a D14 BM assessment was performed. RESULTS: A D14 BM blast proportion < 10% (including blast-free aplastic BM) was observed in 319 patients (82%), 10% to 29% was observed in 31 patients (8%), and ≥30% was observed in 39 patients (10%). The composite complete remission (CR)/complete remission with inadequate platelet recovery (CRp) rates for these groups were 99.7%, 87%, and 79%, respectively. The median event-free survival (EFS) was 49, 33, and 9 months, respectively (P < .001). The median overall survival (OS) was 88, 37, and 21 months, respectively (P < .001). The D14 BM blast group was the only factor predictive for the achievement of CR/CRp (P < .001). According to a multivariate analysis, the D14 BM blast group was independently prognostic for both EFS (hazard ratio [HR], 1.44; 95% confidence interval [CI], 1.12-1.85; P = .004) and OS (HR, 1.45; 95% CI, 1.14-1.85; P = .003). However, when minimal residual disease (MRD) assessment at the time of CR was added to the model, the D14 BM blast group was no longer prognostic for EFS or OS. CONCLUSIONS: An assessment of residual D14 BM blasts in patients with ALL is highly predictive of the achievement of CR with induction chemotherapy and of EFS and OS. However, the D14 BM blast assessment is less prognostic of long-term outcomes when an MRD assessment is also available. Cancer 2016;122:3812-3820.
BACKGROUND: The role of day 14 (D14) bone marrow (BM) assessment in detecting increased blasts in patients undergoing induction for acute lymphoblastic leukemia (ALL) is not well defined. METHODS: This study evaluated 389 adolescent and adult patients with previously untreated Philadelphia chromosome-negative ALL who received frontline induction chemotherapy and for whom a D14 BM assessment was performed. RESULTS: A D14 BM blast proportion < 10% (including blast-free aplastic BM) was observed in 319 patients (82%), 10% to 29% was observed in 31 patients (8%), and ≥30% was observed in 39 patients (10%). The composite complete remission (CR)/complete remission with inadequate platelet recovery (CRp) rates for these groups were 99.7%, 87%, and 79%, respectively. The median event-free survival (EFS) was 49, 33, and 9 months, respectively (P < .001). The median overall survival (OS) was 88, 37, and 21 months, respectively (P < .001). The D14 BM blast group was the only factor predictive for the achievement of CR/CRp (P < .001). According to a multivariate analysis, the D14 BM blast group was independently prognostic for both EFS (hazard ratio [HR], 1.44; 95% confidence interval [CI], 1.12-1.85; P = .004) and OS (HR, 1.45; 95% CI, 1.14-1.85; P = .003). However, when minimal residual disease (MRD) assessment at the time of CR was added to the model, the D14 BM blast group was no longer prognostic for EFS or OS. CONCLUSIONS: An assessment of residual D14 BM blasts in patients with ALL is highly predictive of the achievement of CR with induction chemotherapy and of EFS and OS. However, the D14 BM blast assessment is less prognostic of long-term outcomes when an MRD assessment is also available. Cancer 2016;122:3812-3820.
Authors: H M Kantarjian; S O'Brien; T L Smith; J Cortes; F J Giles; M Beran; S Pierce; Y Huh; M Andreeff; C Koller; C S Ha; M J Keating; S Murphy; E J Freireich Journal: J Clin Oncol Date: 2000-02 Impact factor: 44.544
Authors: V Liso; F Albano; D Pastore; P Carluccio; G Mele; M Lamacchia; A Mestice; G Specchia Journal: Haematologica Date: 2000-12 Impact factor: 9.941
Authors: J B Nachman; H N Sather; M G Sensel; M E Trigg; J M Cherlow; J N Lukens; L Wolff; F M Uckun; P S Gaynon Journal: N Engl J Med Date: 1998-06-04 Impact factor: 91.245
Authors: Adele K Fielding; Jacob M Rowe; Georgina Buck; Letizia Foroni; Gareth Gerrard; Mark R Litzow; Hillard Lazarus; Selina M Luger; David I Marks; Andrew K McMillan; Anthony V Moorman; Bella Patel; Elisabeth Paietta; Martin S Tallman; Anthony H Goldstone Journal: Blood Date: 2013-11-25 Impact factor: 22.113
Authors: Irene Della Starza; Sabina Chiaretti; Maria S De Propris; Loredana Elia; Marzia Cavalli; Lucia A De Novi; Roberta Soscia; Monica Messina; Antonella Vitale; Anna Guarini; Robin Foà Journal: Front Oncol Date: 2019-08-07 Impact factor: 6.244
Authors: Josep-Maria Ribera; Mireia Morgades; Pau Montesinos; Mar Tormo; Daniel Martínez-Carballeira; José González-Campos; Cristina Gil; Pere Barba; Raimundo García-Boyero; Rosa Coll; María Pedreño; Jordi Ribera; Santiago Mercadal; Susana Vives; Andrés Novo; Eulàlia Genescà; Jesús-María Hernández-Rivas; Juan Bergua; María-Luz Amigo; Ferran Vall-Llovera; Pilar Martínez-Sánchez; María Calbacho; Irene García-Cadenas; Antoni Garcia-Guiñon; María-José Sánchez-Sánchez; Marta Cervera; Evarist Feliu; Alberto Orfao Journal: Cancer Med Date: 2020-02-05 Impact factor: 4.452
Authors: S Modvig; H Hallböök; H O Madsen; S Siitonen; S Rosthøj; A Tierens; V Juvonen; L T N Osnes; H Vålerhaugen; M Hultdin; R Matuzeviciene; M Stoskus; M Marincevic; A Lilleorg; M Ehinger; U Norén-Nystrøm; N Toft; M Taskinen; O G Jónsson; K Pruunsild; G Vaitkeviciene; K Vettenranta; B Lund; J Abrahamsson; A Porwit; K Schmiegelow; H V Marquart Journal: Leukemia Date: 2020-12-14 Impact factor: 11.528